aibioAspira Women's Health expands Cleveland Clinic collaboration on AI diagnostics
Tickers AWHL
The master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms.
Key facts
- Company
- Aspira Women's Health Inc. (OTC: AWHL)
- News type
- Company Updates
- Primary source
- Aspira Women's Health Inc. 8-K (2026-05-26)
Aspira Women's Health Inc. (OTCQX: AWHL) and Cleveland Clinic have signed a Master Collaboration and License Agreement to work together on AI-enabled, noninvasive diagnostics for women's health. The companies announced the agreement in a press release dated May 26, 2026, which the company filed with a Form 8-K filed the same day.
The agreement
Under the agreement, the two organizations will collaborate on research projects focused on the discovery and validation of novel biomarker signatures and on the development of advanced analytical models intended to improve diagnostic accuracy, clinical utility and patient care. The agreement also creates a framework for future platform expansion, covering biomarker discovery, data generation, translational development, intellectual property collaboration and clinical research initiatives.
The organizations say they aim to expand patient sample access, strengthen clinical validation capabilities and support the accelerated development and future commercialization of next generation multiomic diagnostics across women's health. The release does not state any financial terms of the agreement.
The initiative will be jointly led by Kevin Elias, M.D., of Cleveland Clinic, and Todd Pappas, Ph.D., chief scientific officer of Aspira Women's Health, alongside multidisciplinary translational research teams. Dr. Elias holds the Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at Cleveland Clinic.
Chief Executive Officer Mike Buhle called the agreement "an important inflection point for Aspira" as the company works to build what he described as a category defining women's health diagnostics platform. Michelle Snider, senior vice president of product commercialization and innovation, said the collaboration strengthens the company's position at the intersection of women's health, artificial intelligence and precision medicine.
About the partner
Cleveland Clinic describes itself as a nonprofit multi-specialty academic medical center that integrates clinical and hospital care with research and education. The release says it was founded in 1921 and describes a 6,725-bed health system that includes 23 hospitals and 300 outpatient facilities. In 2025, the health system recorded 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures.
The company's platform
Aspira describes itself as a company focused on AI-powered, noninvasive diagnostics for women's health. Its OvaWatch test has a negative predictive value of 99% and is used where an initial clinical assessment shows an adnexal mass to be indeterminate or benign. Ova1Plus is a reflex process of two FDA-cleared tests and is used to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. The company says it intends to combine microRNA and protein biomarkers with patient data to improve its ovarian cancer tests, and it has developed what it calls the first-ever non-invasive test designed to identify endometriomas.
Financial position
The company's annual report on Form 10-K, filed April 1, 2026, says its current capital resources are not sufficient to fund its operations for the remainder of 2026. For fiscal 2025 the company reported revenue of $343,000, up from $4,000 in fiscal 2024, and a net loss of $12.8 million, compared with $13.1 million in 2024. Cash from operations was negative $7.0 million in 2025 and negative $12.1 million in 2024. The annual report says the company has been pursuing strategic alternatives and seeking to raise additional capital.
What comes next
The release states no financial terms, no schedule for the first research projects and no clinical milestones, so it does not show what the agreement is worth to Aspira. The 99% negative predictive value, the claim of a first-ever test for endometriomas and the chief executive's phrase "an important inflection point" are the company's own descriptions, and the release offers no data behind them. The annual report shows a net loss of $12.8 million for 2025 and warns that capital resources are not sufficient for the remainder of 2026. The shares are quoted on OTCQX.